TILT Biotherapeutics Ltd

Tiltbio is reshaping cancer treatment by developing innovative investigational therapies that are intended to offer hope to patients with limited treatment options, with an initial focus on platinum-resistant ovarian cancer.

The patented TILT® technology includes modified viruses that are delivered intravenously and are able to reach cancer cells, helping the immune system recognize and attack solid tumors. Intravenous delivery offers the efficiency of the TILT® technology reaching the whole body, potentially targeting primary and metastatic tumors.

For patients with platinum-resistant ovarian cancer in whom surgery and chemotherapy have not been effective (lead indication), Tiltbio is developing an investigational therapy that may offer another option.

Here’s how it works:

• Tiltbio’s technology has been used in Phase I clinical studies in patients with platinum-resistant or refractory ovarian cancer to turn immunologically “cold” tumors (those lacking significant immune-cell infiltration) to “hot” tumors that are active sites for an immune response.

• TILT® technology consist of delivering proprietary oncolytic viruses armed with molecules like cytokines to cancer cells, to help stimulate and enhance T-cell (immune cell) responses.

• TILT-123 (igrelimogene litadenorepvec), Tiltbio’s investigational therapy for platinum-resistant ovarian cancer, is designed for intravenous administration and is the only engineered oncolytic virus armed with two immunostimulatory cytokines: tumor necrosis factor (TNF) and interleukin-2 (IL-2).